U.S. President Donald Trump signed an executive order today aimed at lowering drug prices by aligning them with the prices paid by other countries. Trump had previously announced his intention to address the pharmaceutical market situation in the U.S. However, the reaction of drug manufacturers' stocks indicates that the proposed solution is better than what the market had anticipated.
The key element of the new executive order is the introduction of drug pricing based on the principle of the "Most Favored Nation" (MFN) Pricing. Comparing drug prices in the U.S. with those in other developed countries reveals significant discrepancies, and the new regulation aims to eliminate these differences. According to the order, within the next 30 days, the Secretary of Health will contact drug manufacturers and present price targets in line with the MFN policy. During his previous term, Trump had already attempted to implement a similar solution, so the MFN policy is not entirely new.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appIf companies do not make "significant progress" toward these goals within six months of the order being signed, further measures will be taken to lower prices.
However, the executive order does not specify which drugs will be covered, and its tone is less aggressive than what investors had anticipated. As a result, we are seeing gains in stocks like Eli Lilly (+3.7%), Bristol Myers Squibb (+4%), and Pfizer (+3.4%) during today’s session.
It is worth noting that the issue of resolving drug pricing remains uncertain for now, and considering Trump's previous actions, investors can still expect some twists in this matter.
Eli Lilly breaks a clear downward trend today, led by investors' concerns about Trump's announced changes in U.S. drug pricing. A rebound from the support zone around $761 may indicate a potential recovery for the stocks that saw significant declines last week. Source: xStation
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
